VACCINATION WITH HER-2/NEU AND CEA PEPTIDES IN COLORECTAL CANCER PATIENTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该方案旨在评估由四种结肠癌多肽和GM-CSF组成的疫苗在II、III或IV期结直肠癌患者中的免疫原性。这项研究的目的是确定疫苗是否安全，(B)免疫原性，(C)诱导细胞毒性T细胞对自体和/或MHC匹配的肿瘤细胞的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is designed to assess the immunogenicity of a vaccine comprised of four colon cancer peptides plus GM-CSF in adjuvant in patients with Stage II, III, or IV colorectal cancer. The objectives of this study are to determine if the vaccine is:(a) safe, (b) immunogenic, and (c) induces cytotoxic T-cell responses against autologous and/or MHC-matched tumor cells.